JP2005515757A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005515757A5 JP2005515757A5 JP2003524534A JP2003524534A JP2005515757A5 JP 2005515757 A5 JP2005515757 A5 JP 2005515757A5 JP 2003524534 A JP2003524534 A JP 2003524534A JP 2003524534 A JP2003524534 A JP 2003524534A JP 2005515757 A5 JP2005515757 A5 JP 2005515757A5
- Authority
- JP
- Japan
- Prior art keywords
- sample
- array
- sequence
- nucleic acid
- hybridization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 claims description 225
- 230000014509 gene expression Effects 0.000 claims description 126
- 230000002438 mitochondrial Effects 0.000 claims description 109
- 238000009396 hybridization Methods 0.000 claims description 105
- 210000004027 cells Anatomy 0.000 claims description 88
- 150000007523 nucleic acids Chemical class 0.000 claims description 75
- 108020004707 nucleic acids Proteins 0.000 claims description 70
- 241000282414 Homo sapiens Species 0.000 claims description 56
- 230000004962 physiological condition Effects 0.000 claims description 40
- 210000001519 tissues Anatomy 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 28
- 239000000758 substrate Substances 0.000 claims description 24
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 21
- 108020004999 Messenger RNA Proteins 0.000 claims description 16
- 229920002106 messenger RNA Polymers 0.000 claims description 16
- 210000003205 Muscles Anatomy 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 210000000952 Spleen Anatomy 0.000 claims description 12
- 210000002216 Heart Anatomy 0.000 claims description 11
- 208000006136 Leigh Disease Diseases 0.000 claims description 11
- 239000011521 glass Substances 0.000 claims description 11
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 10
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 10
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 10
- 238000007639 printing Methods 0.000 claims description 10
- 210000004556 Brain Anatomy 0.000 claims description 9
- 102100016568 GPX3 Human genes 0.000 claims description 9
- 101700014249 GPX3 Proteins 0.000 claims description 9
- 210000003734 Kidney Anatomy 0.000 claims description 9
- 210000002027 Muscle, Skeletal Anatomy 0.000 claims description 9
- 210000004185 Liver Anatomy 0.000 claims description 7
- 201000010874 syndrome Diseases 0.000 claims description 7
- 101710025184 SLC25A5 Proteins 0.000 claims description 6
- 102100004239 SOD2 Human genes 0.000 claims description 4
- 102000026834 Surf-1 protein Human genes 0.000 claims description 4
- 108010008042 Surf-1 protein Proteins 0.000 claims description 4
- 230000037149 energy metabolism Effects 0.000 claims description 4
- 108010045815 superoxide dismutase 2 Proteins 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 210000000056 organs Anatomy 0.000 claims description 3
- 102100010314 SLC25A5 Human genes 0.000 claims 3
- -1 NDL4 Proteins 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 230000001605 fetal Effects 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 64
- 229920000460 Mitochondrial DNA Polymers 0.000 description 52
- 108020005196 Mitochondrial DNA Proteins 0.000 description 43
- 230000001105 regulatory Effects 0.000 description 36
- 101710026488 SOD2 Proteins 0.000 description 32
- 238000002493 microarray Methods 0.000 description 29
- 230000035790 physiological processes and functions Effects 0.000 description 27
- 230000035772 mutation Effects 0.000 description 26
- 230000002068 genetic Effects 0.000 description 25
- 230000010627 oxidative phosphorylation Effects 0.000 description 25
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 229920002676 Complementary DNA Polymers 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 230000000875 corresponding Effects 0.000 description 15
- 210000003470 Mitochondria Anatomy 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 230000000295 complement Effects 0.000 description 13
- 102100004384 GPX1 Human genes 0.000 description 12
- 208000003269 Mitochondrial Disease Diseases 0.000 description 12
- 108010086596 glutathione peroxidase GPX1 Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 206010059512 Apoptosis Diseases 0.000 description 8
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 8
- 229920002248 Nuclear DNA Polymers 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- XHVDAQLNUQLQKW-UHFFFAOYSA-K manganese(3+);4-[10,15,20-tris(4-carboxyphenyl)porphyrin-22,24-diid-5-yl]benzoic acid;chloride Chemical compound [Cl-].[Mn+3].C1=CC(C(=O)O)=CC=C1C(C1=CC=C([N-]1)C(C=1C=CC(=CC=1)C(O)=O)=C1C=CC(=N1)C(C=1C=CC(=CC=1)C(O)=O)=C1C=CC([N-]1)=C1C=2C=CC(=CC=2)C(O)=O)=C2N=C1C=C2 XHVDAQLNUQLQKW-UHFFFAOYSA-K 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 229920001850 Nucleic acid sequence Polymers 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000513 principal component analysis Methods 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 102000015930 Lon protease Human genes 0.000 description 6
- 229920000272 Oligonucleotide Polymers 0.000 description 6
- LLKYUHGUYSLMPA-UHFFFAOYSA-N Phosphoramidite Chemical compound NP([O-])[O-] LLKYUHGUYSLMPA-UHFFFAOYSA-N 0.000 description 6
- 108010023294 Protease La Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000001413 cellular Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000010195 expression analysis Methods 0.000 description 6
- 230000002414 glycolytic Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 229920000023 polynucleotide Polymers 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 206010053643 Neurodegenerative disease Diseases 0.000 description 5
- 241000282579 Pan Species 0.000 description 5
- 102000004962 Voltage-Dependent Anion Channels Human genes 0.000 description 5
- 108090001129 Voltage-Dependent Anion Channels Proteins 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 230000001264 neutralization Effects 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108040000931 ATP:ADP antiporter activity proteins Proteins 0.000 description 4
- 102000026802 ATP:ADP antiporter activity proteins Human genes 0.000 description 4
- 108009000447 Amino Acid metabolism Proteins 0.000 description 4
- 102100006374 CASP1 Human genes 0.000 description 4
- 108090000426 Caspase 1 Proteins 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000036740 Metabolism Effects 0.000 description 4
- 229940076788 Pyruvate Drugs 0.000 description 4
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 4
- 101710025181 SLC25A4 Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000037354 amino acid metabolism Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000003078 antioxidant Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004748 cultured cells Anatomy 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000007417 hierarchical cluster analysis Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002503 metabolic Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000035786 metabolism Effects 0.000 description 4
- 230000001575 pathological Effects 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101700011961 DPOM Proteins 0.000 description 3
- 102000005731 EC 5.3.1.9 Human genes 0.000 description 3
- 108010070600 EC 5.3.1.9 Proteins 0.000 description 3
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 3
- 229940088598 Enzyme Drugs 0.000 description 3
- 229960001031 Glucose Drugs 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 101710029649 MDV043 Proteins 0.000 description 3
- 102100017929 MT-ND6 Human genes 0.000 description 3
- 101710028342 MT-ND6 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108009000379 Mitochondrial Gene Expression Proteins 0.000 description 3
- 206010028640 Myopathy Diseases 0.000 description 3
- 210000004940 Nucleus Anatomy 0.000 description 3
- 108009000578 Oxidative Stress Proteins 0.000 description 3
- 101700061424 POLB Proteins 0.000 description 3
- 108010003541 Platelet Activating Factor Proteins 0.000 description 3
- 101700054624 RF1 Proteins 0.000 description 3
- 229940045145 Uridine Drugs 0.000 description 3
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 3
- 101700083020 aac Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000000158 apoptosis inhibitor Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000007621 cluster analysis Methods 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004898 mitochondrial function Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 201000010770 muscular disease Diseases 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000002093 peripheral Effects 0.000 description 3
- 230000007129 protein targeting to mitochondrion Effects 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- 230000001603 reducing Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091007521 restriction endonucleases Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000005204 segregation Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 102100015655 BCL2L1 Human genes 0.000 description 2
- 210000000133 Brain Stem Anatomy 0.000 description 2
- 102100005565 CPOX Human genes 0.000 description 2
- 210000003483 Chromatin Anatomy 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- 108009000097 DNA Replication Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 108010094074 EC 1.3.3.3 Proteins 0.000 description 2
- 102000013009 EC 2.7.1.40 Human genes 0.000 description 2
- 108020005115 EC 2.7.1.40 Proteins 0.000 description 2
- 102000008013 Electron Transport Complex I Human genes 0.000 description 2
- 108010089760 Electron Transport Complex I Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 2
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102100014728 MECR Human genes 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N Manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 210000004165 Myocardium Anatomy 0.000 description 2
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 2
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 2
- 101710003528 NDUFS8 Proteins 0.000 description 2
- 102100000492 NDUFS8 Human genes 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 108010012715 Superoxide Dismutase Proteins 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 229920001949 Transfer RNA Polymers 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000002715 bioenergetic Effects 0.000 description 2
- 230000037348 biosynthesis Effects 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 108091006028 chimera Proteins 0.000 description 2
- 238000007418 data mining Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010046 dilated cardiomyopathy Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004129 fatty acid metabolism Effects 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229920002111 mitochondrial RNA Polymers 0.000 description 2
- 230000026326 mitochondrial transport Effects 0.000 description 2
- 108010057157 mouse Nrbf1 protein Proteins 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000009623 myopathy Diseases 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002285 radioactive Effects 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000003252 repetitive Effects 0.000 description 2
- 230000035812 respiration Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000004805 robotic Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000004544 spot-on Substances 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional Effects 0.000 description 2
- 239000011778 trisodium citrate Substances 0.000 description 2
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S Ribosomal RNA Proteins 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- 102100016913 ACO1 Human genes 0.000 description 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 101700007682 BNIP3 Proteins 0.000 description 1
- 210000004227 Basal Ganglia Anatomy 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- 208000008581 Brain Disease Diseases 0.000 description 1
- 101700014488 CLPB Proteins 0.000 description 1
- 102100018248 CYB5R4 Human genes 0.000 description 1
- 102000003846 Carbonic Anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic Anhydrases Proteins 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- 108090000552 Caspase 2 Proteins 0.000 description 1
- 102000004046 Caspase 2 Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 210000003710 Cerebral Cortex Anatomy 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 Chloramphenicol Drugs 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- OHOQEZWSNFNUSY-UHFFFAOYSA-N Cy3-bifunctional dye zwitterion Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C2=CC=C(S(O)(=O)=O)C=C2C(C)(C)C1=CC=CC(C(C1=CC(=CC=C11)S([O-])(=O)=O)(C)C)=[N+]1CCCCCC(=O)ON1C(=O)CCC1=O OHOQEZWSNFNUSY-UHFFFAOYSA-N 0.000 description 1
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-N Deoxycytidine triphosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N Deoxyguanosine triphosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 206010013642 Drooling Diseases 0.000 description 1
- 208000010118 Dystonia Diseases 0.000 description 1
- 102000013460 EC 1.1.1.37 Human genes 0.000 description 1
- 108010026217 EC 1.1.1.37 Proteins 0.000 description 1
- 108030005700 EC 1.6.2.2 Proteins 0.000 description 1
- 102000004420 EC 2.7.3.2 Human genes 0.000 description 1
- 108010042126 EC 2.7.3.2 Proteins 0.000 description 1
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 1
- 108010009924 EC 4.2.1.3 Proteins 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 101700008821 EXO Proteins 0.000 description 1
- 101700083023 EXRN Proteins 0.000 description 1
- 102000015782 Electron Transport Complex III Human genes 0.000 description 1
- 108010024882 Electron Transport Complex III Proteins 0.000 description 1
- 108091003147 Electron Transport Complex IV Proteins 0.000 description 1
- 102000011686 Electron Transport Complex IV Human genes 0.000 description 1
- 206010014623 Encephalopathy Diseases 0.000 description 1
- 206010014625 Encephalopathy Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 108010000728 Excitatory Amino Acid Transporter 3 Proteins 0.000 description 1
- 229920002760 Expressed sequence tag Polymers 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- 102000003869 Frataxin Human genes 0.000 description 1
- 108090000217 Frataxin Proteins 0.000 description 1
- 102100005993 G6PD Human genes 0.000 description 1
- 102100006425 GAPDH Human genes 0.000 description 1
- 101710008404 GAPDH Proteins 0.000 description 1
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 102000006587 Glutathione Peroxidase Human genes 0.000 description 1
- 108020004973 Glutathione Peroxidase Proteins 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229940096919 Glycogen Drugs 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 108009000244 Heme Biosynthesis Proteins 0.000 description 1
- 101710006546 Hsp70Aa Proteins 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- SAUCHDKDCUROAO-VKHMYHEASA-N L-2-amino-3-oxobutanoic acid zwitterion Chemical compound CC(=O)[C@H](N)C(O)=O SAUCHDKDCUROAO-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenases Human genes 0.000 description 1
- 108091000084 L-lactate dehydrogenases Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 208000006443 Lactic Acidosis Diseases 0.000 description 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100016690 MT-ATP6 Human genes 0.000 description 1
- 101710043454 MT-ATP6 Proteins 0.000 description 1
- 102100010405 MT-ATP8 Human genes 0.000 description 1
- 101710043453 MT-ATP8 Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027378 Mental retardation Diseases 0.000 description 1
- 208000005894 Mitochondrial Myopathy Diseases 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000000818 NADP Transhydrogenases Human genes 0.000 description 1
- 108010001609 NADP Transhydrogenases Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010029864 Nystagmus Diseases 0.000 description 1
- 208000001749 Optic Atrophy Diseases 0.000 description 1
- 208000007610 Optic Atrophy, Hereditary, Leber Diseases 0.000 description 1
- 210000003733 Optic Disk Anatomy 0.000 description 1
- 210000001328 Optic Nerve Anatomy 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 101710042135 PPi-PFK Proteins 0.000 description 1
- 102100003662 PRDX3 Human genes 0.000 description 1
- 101700082418 PRDX3 Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 235000002343 Primula veris Nutrition 0.000 description 1
- 240000003122 Primula vulgaris Species 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102100017237 SLC1A1 Human genes 0.000 description 1
- 102100006313 SURF4 Human genes 0.000 description 1
- 108060007966 SURF4 Proteins 0.000 description 1
- 102100018992 SYPL1 Human genes 0.000 description 1
- 101700051135 SYPL1 Proteins 0.000 description 1
- 210000000278 Spinal Cord Anatomy 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N Succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- 101700079214 TBA1 Proteins 0.000 description 1
- 101710029758 TIMM17A Proteins 0.000 description 1
- 101700029414 TSPO Proteins 0.000 description 1
- 102000033187 TSPO Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 210000001103 Thalamus Anatomy 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 102000012290 Voltage-Dependent Anion Channel 1 Human genes 0.000 description 1
- 108010022133 Voltage-Dependent Anion Channel 1 Proteins 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002424 anti-apoptotic Effects 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 238000003556 assay method Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 101700027839 bah Proteins 0.000 description 1
- 230000001851 biosynthetic Effects 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 210000003850 cellular structures Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-J dATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-J 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 210000002257 embryonic structures Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 230000030414 genetic transfer Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 201000006347 intellectual disability Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 101710030587 ligN Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 101700077585 ligd Proteins 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 230000004065 mitochondrial dysfunctions Effects 0.000 description 1
- 201000002169 mitochondrial myopathy Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 210000000663 muscle cells Anatomy 0.000 description 1
- 230000001338 necrotic Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000002981 neuropathic Effects 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 108010007425 oligomycin sensitivity-conferring protein Proteins 0.000 description 1
- 230000004380 optic nerve Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 230000001991 pathophysiological Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 101710036149 pfk-1.2 Proteins 0.000 description 1
- 101700087004 pfkA1 Proteins 0.000 description 1
- 101700035696 pfkB Proteins 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000003234 polygenic Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000000861 pro-apoptotic Effects 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 230000007055 protein processing involved in protein targeting to mitochondrion Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 101700000320 rcd1 Proteins 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000002477 vacuolizing Effects 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 238000002759 z-score normalization Methods 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31632301P | 2001-08-30 | 2001-08-30 | |
| CA002356540A CA2356540A1 (fr) | 2001-08-30 | 2001-08-31 | Sequences d'adn exprimees jouant un role dans les fonctions mitochondriales |
| PCT/US2002/027886 WO2003020220A2 (fr) | 2001-08-30 | 2002-08-30 | Reseaux d'expression de biologie mitochondriale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005515757A JP2005515757A (ja) | 2005-06-02 |
| JP2005515757A5 true JP2005515757A5 (fr) | 2006-01-26 |
Family
ID=25682709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524534A Pending JP2005515757A (ja) | 2001-08-30 | 2002-08-30 | ミトコンドリア生物学発現アレイ |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1432823A4 (fr) |
| JP (1) | JP2005515757A (fr) |
| WO (1) | WO2003020220A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE032575T2 (en) | 2003-05-21 | 2017-10-30 | Andes Biotechnologies S A | Compounds and Oligonucleotides for Diagnosis and Treatment of Cancer and Cancer Prevention |
| WO2004108960A2 (fr) * | 2003-06-09 | 2004-12-16 | Decode Genetics Ehf. | Methodes de prevision de la sensibilite a des medicaments chez des patients souffrant d'hypertension |
| EP1524523A1 (fr) * | 2003-10-17 | 2005-04-20 | Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts | Utilisation de ADAM 12 pour le diagnostic et le traitement de pré-éclampsie |
| WO2005058142A2 (fr) * | 2003-12-16 | 2005-06-30 | Emory University | Diagnostic du diabete |
| CN114990160B (zh) * | 2022-06-13 | 2024-02-02 | 昆明医科大学 | 一种Navβ2-ICD低表达转基因鼠模型的构建方法及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69829402T2 (de) * | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
| CA2329709A1 (fr) * | 1998-04-24 | 1999-11-04 | Mitokor | Composes et methodes de traitement de maladies liees aux mitochondries |
| US6218117B1 (en) * | 1998-06-15 | 2001-04-17 | Mitokor | Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios |
| AU3900600A (en) * | 1999-03-16 | 2000-10-04 | Mitokor | Differential expression of organellar gene products |
-
2002
- 2002-08-30 WO PCT/US2002/027886 patent/WO2003020220A2/fr active Application Filing
- 2002-08-30 JP JP2003524534A patent/JP2005515757A/ja active Pending
- 2002-08-30 EP EP02768777A patent/EP1432823A4/fr not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060099578A1 (en) | Mitochondrial biology expression arrays | |
| US20140272951A1 (en) | Methods of identifying mutations in nucleic acid | |
| US20080241839A1 (en) | Method for correlating differential brain images and genotypes; genes that correlate with differential brain images | |
| US20060177847A1 (en) | Markers for metabolic syndrome obesity and insulin resistance | |
| JP2009502141A (ja) | ウシ科動物における背最長筋ピーク力、筋肉内脂肪、小売牛肉歩留および正味飼料摂取量から選択される形質の査定方法 | |
| AU2009275988B2 (en) | A genetic marker test for Brachyspina and fertility in cattle | |
| TW200923103A (en) | ALPK1 gene variants in diagnosis risk of gout | |
| JP2005515757A5 (fr) | ||
| JP5427352B2 (ja) | ヒト体脂肪量と関連する遺伝子多型に基づく肥満発症リスクの判定方法 | |
| EP1829979B1 (fr) | Procede d'identification de gene avec une expression variable | |
| WO2003020220A2 (fr) | Reseaux d'expression de biologie mitochondriale | |
| JP2010502205A (ja) | Ｇｔｐシクロヒドロラーゼ１遺伝子（ｇｃｈ１）中の疼痛保護的ハプロタイプの診断のためのｓｎｐの使用 | |
| JP5897704B2 (ja) | ブラキスパイナ突然変異の検出 | |
| US8334096B2 (en) | Methods and compositions related to arrhythmogenic right ventricular cardiomyopathy (ARVC) | |
| JP2005511095A (ja) | Ｄ−アミノ酸オキシダーゼのバイアレリック・マーカー及びその用途 | |
| JP2010515467A (ja) | 心筋梗塞及び心不全における診断マーカー及び薬剤設計のためのプラットホーム | |
| JP4998874B2 (ja) | 炎症性疾患の判定方法 | |
| EP1799852B1 (fr) | Association d'expression genetique et de troubles psychiatriques | |
| AU2002331789A1 (en) | Mitochondrial biology expression arrays | |
| JP2005516626A (ja) | Ｔｐｍｔのヒト遺伝子における多型ならびに診断的適用および治療的適用におけるその使用方法 | |
| JP2021073993A (ja) | イヌ白内障の検査方法、イヌ白内障の検査をするための試薬、及びイヌ白内障の検査キット | |
| EP2149611A1 (fr) | Test de marqueur génétique pour la brachyspina et la fertilité pour le bétail | |
| US20130323733A1 (en) | Methods of assessing a risk of developing necrotizing meningoencephalitis | |
| JP2004215647A (ja) | ２型糖尿病関連遺伝子 | |
| Lin | Candidate gene expression and SNP analyses of toxin-induced dilated cardiomyopathy in the turkey (Meleagris gallopavo) |